The primary analyses revealed an SCCAI drop of 33.3 % in the placebo group ( from 9.0 to 6.0 points ) compared with 44.3 % in the 0.8 g LT-02 ( from 8.8 to 4.9 , P > 0.05 ) and 40.7 % in the 1.6 g groups ( from 8.6 to 5.1 , P > 0.05 ) .